Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

A commentary on "association of functional outcomes between intravenous tirofiban and endovascular thrombectomy in imaging-screened patients with large vessel occlusion stroke: a secondary analysis of randomized clinical trial". (PubMed, Int J Surg) - No abstract available

Clinical • Journal • Cardiovascular

The inhibitory effect of antiplatelet drugs on spontaneous platelet aggregation on glass surfaces: an analysis based on microscopic three-dimensional topography. (PubMed, J Thromb Thrombolysis) - "Ticagrelor, eptifibatide, and tirofiban dose-dependently decreased both Vol and CS-area...GPIb-IX-von Willebrand factor (vWF) inhibitors (4 μM) and indomethacin (4 μM) significantly reduced both Vol and CS-area, with a smaller reduction in CS-area compared to Vol. In patients, aspirin alone significantly reduced Vol, while clopidogrel, aspirin combined with clopidogrel, and Xuesaitong significantly decreased both Vol and CS-area. Our novel analytical strategy is capable of distinguishing the pharmacological effects of various antiplatelet agents without the need for exogenous agonists, suggesting that this system may aid in the determination of the appropriate type and dose of the antiplatelet agent in the clinical setting."

Journal

Serum Lipid Profiles as Predictors of Hemorrhagic Transformation After Thrombolysis in Acute Cerebral Infarction: A Prospective Study. (PubMed, Curr Neurovasc Res) - "Patients with ACI undergoing IVT who had higher baseline NIHSS scores, lower TC, higher HDL, and a higher T/H ratio were at increased risk of HT, which was also associated with long-term outcomes. The T/H ratio may be a valuable predictor of HT following IVT."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Hypertension

A disproportionality analysis of real-world adverse events associated with tirofiban from the FAERS database. (PubMed, Sci Rep) - "Furthermore, other relatively rare but statistically significant AEs were identified, including acute respiratory failure, hemolysis, prolonged activated partial thromboplastin time (APTT), coagulopathy, and disseminated intravascular coagulation (DIC). The temporal analysis showed the median onset time of AEs was 1 day, which urges immediate monitoring after drug administration, such as symptom surveillance and complete blood count evaluation."

Adverse events • Journal • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Ischemic stroke • Respiratory Diseases • Thrombocytopenia • Thrombosis

ATTRACTION: Tirofiban After Successful MT Recanalization in AIS (clinicaltrials.gov) - P2/3 | N=1360 | Recruiting | Sponsor: Xiang Luo | Trial completion date: Sep 2027 ➔ Jan 2026 | Trial primary completion date: Mar 2027 ➔ Jan 2026

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Effects of intracoronary tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention [WITHDRAWN] (ESC-WCC 2025) - "The use of intracoronary Tirofiban in the setting of CNR in STEMI patients undergoing PPCI may be beneficial in the improvement of TIMI flow and myocardial blush grade with no benefit noted regarding in-hospital MACE and mortality."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Thrombosis

Tirofiban-induced acute profound thrombocytopenia in endovascular therapy for acute ischemic stroke: a rare case report. (PubMed, BMC Neurol) - No abstract available

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombocytopenia • Vascular Neurology

Intravenous tenecteplase thrombolysis and endovascular bridging intra-arterial tirofiban injection therapy in a pediatric case of acute ischemic stroke. (PubMed, BMC Neurol) - "Pediatric AIS exhibits variable clinical manifestations, requiring head MRI for definitive diagnosis. Early initiation of intravenous thrombolysis with tenecteplase, combined with targeted intra-arterial tirofiban injection, demonstrates potential as a safe and effective therapeutic approach in pediatric ischemic stroke management."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Ischemic stroke • Pediatrics

Drug response testing for elective carotid artery stenting: Prevalence of non-response to aspirin and clopidogrel and influence on post-interventional occurrence of cerebral ischemia. (PubMed, Neuroradiol J) - "BackgroundThe patient-associated prevalence of Clopidogrel (CPG)-and Aspirin (ASS)-nonresponse is not well understood and varies depending on the patient population. Under these conditions, the responder status did not influence post-interventional cerebral infarction patterns.ConclusionAntiplatelet non-response, especially for CPG, is very frequent in patients undergoing CAS. When bridging patients with tirofiban during intervention, responder status had no influence on post-interventional cerebral infarction patterns."

Journal • Cardiovascular • CNS Disorders • Ischemic stroke

Emergent carotid artery stenting with tirofiban in a patient with traumatic intracranial hemorrhage and carotid artery dissection: a case report. (PubMed, Front Med (Lausanne)) - "For patients with AIS due to CAD complicated by ICH, eCAS combined with tirofiban may offer clinical benefits. However, further research is still needed to confirm our findings."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Case Report: Endovascular thrombectomy for acute ischemic stroke with bilateral internal carotid artery fibromuscular dysplasia. (PubMed, Front Cardiovasc Med) - "Intraoperatively, tirofiban was used for anti-thrombotic therapy, and postoperative management included aspirin and statin therapy for secondary prevention...FMD is a rare non-atherosclerotic disease, with cerebral vessel involvement being relatively common and presenting a variety of clinical symptoms, which poses challenges in diagnosis and treatment. For patients with FMD accompanied by acute vascular occlusion, endovascular mechanical thrombectomy is an effective treatment option, and in terms of treatment strategy, combining anti-platelet therapy can effectively improve neurological function and achieve a favorable prognosis."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders • Gout • Inflammatory Arthritis • Ischemic stroke • Rheumatology

Validation of an in vitro testing platform for intra-arterial thrombolytics on human thrombectomy retrieved clots. (PubMed, J Neurointerv Surg) - "This study supports the use of clot based in vitro models with autologous plasma for standardized drug testing for patients with AIS. Sequential administration of rtPA and tirofiban resulted in greater clot degradation than either agent alone. Further studies are needed to confirm clinical applicability and optimize dual thrombolytic strategies."

Journal • Preclinical • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders

Tirofiban in Acute Ischemic Stroke: Mechanistic Rationale, Clinical Advances, and Emerging Therapeutic Strategies. (PubMed, Drugs) - "Given its strong antiplatelet action and potential protective effects on brain tissue, tirofiban continues to gain interest as a treatment for acute ischemic stroke. This review summarizes key studies published since 2018, based on a structured literature search of PubMed, Embase, and Web of Science through May 2025, with the goal of guiding future research and improving clinical integration."

Journal • Review • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Nephrology • Renal Disease

PEARL-TIRO: Intravenous Tirofiban After Delayed Thrombolysis in Stroke (clinicaltrials.gov) - P3 | N=852 | Not yet recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

New P3 trial • Cardiovascular • Ischemic stroke

Intravenous Tirofiban for Preventing Acute In-Stent Thrombosis in Emergent Carotid Artery Stenting: a Systematic Review and Meta-Analysis. (PubMed, Clin Neuroradiol) - "Tirofiban appears to reduce the risk of acute in-stent thrombosis after eCAS without increasing the incidence of hemorrhagic complications or mortality. Further randomized trials are needed to validate these findings and define optimal periprocedural antiplatelet strategies."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombosis

Predictors of infarction and outcomes in capsular warning syndrome: a retrospective observational study. (PubMed, Front Neurol) - "Tirofiban may improve short-term outcomes in infarcted patients. Prospective multicenter studies are needed to validate these findings."

Journal • Observational data • Retrospective data • Atherosclerosis • Cardiovascular • CNS Disorders

Mechanical thrombectomy combined with tirofiban for treatment of acute intracranial atherosclerotic cerebral infarction: clinical observations and effect on serum inflammatory factors. (PubMed, Am J Transl Res) - "Tirofiban combined with MT improves revascularization in patients, reduces inflammation and neurobiochemical damage, enhances neurological function, and lowers the risk of re-occlusion in patients with acute intracranial large artery atheromatous cerebral infarction."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders • Oncology • CRP • IL6 • MBP • TNFA

TiMIS: Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke (clinicaltrials.gov) - P4 | N=580 | Recruiting | Sponsor: Second Affiliated Hospital of Soochow University

New P4 trial • Cardiovascular • Ischemic stroke

Single antiplatelet therapy and tirofiban bridged with surface modified flow diverters for ruptured blood blister-like aneurysms: single center experience and systematic review. (PubMed, J Neurointerv Surg) - "Surface modified FDS with SAPT and tirofiban bridging appears to be a promising treatment option for ruptured BBAs, offering high occlusion rates with minimal thromboembolic and hemorrhagic complications. Larger prospective studies are needed to validate these findings."

Journal • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Analysis of the effectiveness of combined CT angiography, MMP-9, and PAF testing in the assessment of vascular restenosis in acute coronary syndromes after atorvastatin combined with tirofiban therapy. (PubMed, J Med Biochem) - "It was determined that 124 patients and 21 patients had poor CTA images, and logistic regression analysis showed that shorter breath-hold time and arrhythmia were independent risk factors for poor CTA image quality. CTA, MMP-9 and PAF are excellent for diagnosing stenosis after ACS, and shorter breath-hold time and arrhythmia are all independent risk factors for poor CTA image quality."

Journal • Acute Coronary Syndrome • Cardiovascular • MMP9

INSIST-BT: Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (clinicaltrials.gov) - P3 | N=884 | Not yet recruiting | Sponsor: General Hospital of Shenyang Military Region

New P3 trial • Cardiovascular • Ischemic stroke

The Role of Intravenous Tirofiban in Patients Undergoing Endovascular Treatment for Acute Intracranial Atherosclerotic Occlusion. (PubMed, J Stroke Cerebrovasc Dis) - P=N/A | "The use of intravenous tirofiban as an adjunctive treatment can potentially improve the prognosis of patients undergoing endovascular treatment for intracranial atherosclerotic large vessel occlusion."

Journal • Atherosclerosis • Cardiovascular • Ischemic stroke

Safety and Efficacy of Ultra-Early Tirofiban Treatment Post Intravenous Thrombolysis in Non-Cardioembolic Acute Ischemic Stroke Patients (ChiCTR) - P4 | N=501 | Not yet recruiting | Sponsor: Army Medical Center of PLA; Army Medical Center of PLA

New P4 trial • Cardiovascular • Ischemic stroke

A Study of the Efficacy and Safety of Tirofiban Versus Alteplase in the Treatment of Acute Mild Ischemic Stroke (ChiCTR) - P=N/A | N=400 | Not yet recruiting | Sponsor: China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University

New trial • Cardiovascular • Ischemic stroke

Safety and efficacy of adjunctive intravenous tirofiban after successful endovascular thrombectomy in patients with large vessel occlusion stroke (ChiCTR) - P4 | N=706 | Recruiting | Sponsor: Xihua County Peoples Hospital; Xihua County Peoples Hospital

New P4 trial • Cardiovascular